Angelini Ventures and EIB back RougeTx's $58M Series A, advancing a first-in-class treatment for a rare bleeding disorder 10/6/2026 Category: INVESTMENTS
Portfolio Company Freya Biosciences Recognized Among Fierce Biotech's Fierce 15 10/5/2026 Category: PORTFOLIO NEWS
Aptadir Closes €40M Seed Round to Advance RNA Therapeutics for Fragile X Syndrome 9/29/2026 Category:
Angelini Ventures and the EIB Invest €17 Million in MMI, Advancing Robotic Microsurgery 9/16/2026 Category: INVESTMENTS
Angelini Ventures Invests in Epicrispr Biotechnologies' $90M Series C to Advance First-in-Class Epigenetic Therapy for FSHD 8/10/2026 Category:
Angelini Ventures